MedTrace Logo

Remegal Different Doses in Patients With Refractory Partial Seizures

NCT01179854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine weather different doses of Remegal are effective,safety and tolerant in Additional Therapy for Patients With Refractory Partial Seizures and pharmacokinetics definition

Conditions

  • Drug Safety
  • Normal Drug Tolerance
  • Self Efficacy

Interventions

DRUG

Remegal

Drug/ placebo

Sponsors & Collaborators

  • Valexfarm

    lead INDUSTRY

Principal Investigators

  • Dorogov Nikolay, MD, PhD · MUZ"City Clinic №4"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-11-30
Completion
2011-09-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01179854 on ClinicalTrials.gov